Natera, Aveta partner on late-stage head and neck cancer trial
Natera, Aveta partner on late-stage head and neck cancer trial June 29 (Reuters) - Genetic testing firm Natera NTRA.O and cancer drug developer Aveta Biomics said on Monday they have partnered on a late-stage study of an experimental therapy for head and neck cancer, in a bid to improve how patients' response to treatment is monitored.
Here are some details:
The study will test Aveta's APG-157, an experimental oral therapy designed to help the body fight tumors, in patients with locally advanced head and neck cancer.
Natera said its Signatera test will be used in the study to assess molecular residual disease and treatment response, and will serve as a secondary endpoint.
The companies said the test will be used before, during and after treatment to monitor patients' response.
Aveta Biomics said the study will enroll about 826 patients globally, including in North America, Europe, Asia-Pacific and Australia.
It said the study builds on data from a mid-stage trial showing the therapy helped control tumors and showed encouraging survival outcomes.
The trial is expected to begin enrollment in the second half of 2026, the companies said.
(Reporting by Sahil Pandey in Bengaluru; Editing by Diti Pujara)
((Sahil.Pandey@thomsonreuters.com;))
Recent news on Natera
See all newsBrief: FDA Grants Breakthrough Device Designation For Natera’S Multi-Cancer Early Detection Assay
Brief: Alliance Foundation Trials And Natera Announce Aft-70 Navigate A Global, Randomized, Phase Iii Trial Evaluating Genentech’S Oral Selective Estrogen Receptor Degrader With Signatera Mrd-Guided Cdk4/6 Inhibitor Therapy In Breast Cancer
US RESEARCH ROUNDUP-Chevron, Exxon Mobil, GoDaddy
Brief: Natera Says Signatera Commercial Launch In Japan Expected In 1H 2027
Brief: Natera To Support New Clinical Trial Assessing Ctdna Dynamics With Latitud In Advanced Skin Cancers